Education
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics (AQST)
NASDAQ:AQST
AQST Stock Chart & Stats
$6.21
-$0.11(-3.57%)
At close: 4:00 PM EST
$6.21
-$0.11(-3.57%)
Day’s Range― - ―
52-Week Range$2.12 - $7.55
Previous CloseN/A
Volume606.88K
Average Volume (3M)2.16M
Market Cap
$757.64M
Enterprise Value$617.97M
Total Cash (Recent Filing)$129.06M
Total Debt (Recent Filing)$128.86M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Mar 10, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding122,003,110
10 Day Avg. Volume2,287,231
30 Day Avg. Volume2,158,565
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-5.13
Price to Sales (P/S)5.36
P/FCF Ratio-8.60
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue14.24
Enterprise Value/Gross Profit23.62
Enterprise Value/Ebitda-12.71
Forecast
1Y Price Target
$8.40Price Target Upside35.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial PreparednessExpansion of commercial and medical infrastructure, strategic commercial hires, and strong key opinion leader support signal robust launch readiness and potential for accelerated prescriber uptake.
Differentiated Product ProfileA device-free, needle-free sublingual film offering rapid onset and easy portability addresses needle aversion and auto-injector limitations, which could drive strong prescription demand if approved.
International Regulatory FeedbackPositive feedback from European regulators that no additional clinical trials are needed, along with planned submissions in Canada and the United Kingdom, supports broader market access and lowers global development burden.
Bears Say
Analyst Sentiment And Valuation PressureAn analyst lowered the price target due to unexpected regulatory ambiguity, which may pressure investor sentiment and the stock's valuation.
Reimbursement And Access ChallengesPotential reimbursement hurdles for a novel delivery format could limit patient access and slow uptake even after regulatory approval.
US Regulatory UncertaintyLack of clarity about Food and Drug Administration–identified deficiencies and an ongoing review that may request additional information increases uncertainty around US approval prospects.
Aquestive Therapeutics News
AQST FAQ
What was Aquestive Therapeutics’s price range in the past 12 months?
Aquestive Therapeutics lowest stock price was $2.12 and its highest was $7.55 in the past 12 months.
What is Aquestive Therapeutics’s market cap?
Aquestive Therapeutics’s market cap is $757.64M.
When is Aquestive Therapeutics’s upcoming earnings report date?
Aquestive Therapeutics’s upcoming earnings report date is Mar 10, 2026 which is in 57 days.
How were Aquestive Therapeutics’s earnings last quarter?
Aquestive Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.128 by -$0.012.
Is Aquestive Therapeutics overvalued?
According to Wall Street analysts Aquestive Therapeutics’s price is currently Undervalued.
Does Aquestive Therapeutics pay dividends?
Aquestive Therapeutics does not currently pay dividends.
What is Aquestive Therapeutics’s EPS estimate?
Aquestive Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Aquestive Therapeutics have?
Aquestive Therapeutics has 122,003,110 shares outstanding.
What happened to Aquestive Therapeutics’s price movement after its last earnings report?
Aquestive Therapeutics reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.128. Following the earnings report the stock price went up 2.167%.
Which hedge fund is a major shareholder of Aquestive Therapeutics?
Currently, no hedge funds are holding shares in AQST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aquestive Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.40 (35.27% Upside)
$8.40 (35.27% Upside)
Blogger Sentiment
Bullish
AQST Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
48.75%
Trailing 12-Months
Company Description
Aquestive Therapeutics
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
AQST Company Deck
AQST Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call emphasized strategic progress towards Anaphylm's FDA approval and significant financing achievements, fostering optimism about the product's launch and market potential. However, financial challenges such as increased net loss and decreased revenue highlight ongoing operational hurdles.View all AQST earnings summariesAQST Stock 12 Month Forecast
Average Price Target
$8.40
▲(35.27% Upside)
Technical Analysis
Emergent Biosolutions
―
SIGA Technologies
―
Esperion
―
Organogenesis Holdings
―
Evolus
―
Ownership Overview
2.81% Insiders
6.76% Mutual Funds
26.81% Other Institutional Investors
56.17% Public Companies and
Individual Investors